サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1794527

核薬局の世界市場

Nuclear Pharmacy

出版日
ページ情報
英文 275 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.16円
核薬局の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 275 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

核薬局の世界市場は2030年までに86億米ドルに達する

2024年に61億米ドルと推定される核薬局の世界市場は、2024年から2030年にかけてCAGR 5.8%で成長し、2030年には86億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである施設タイプは、CAGR 4.5%を記録し、分析期間終了時には48億米ドルに達すると予測されます。商業用タイプセグメントの成長率は、分析期間でCAGR 7.7％と推定されます。

米国市場は17億米ドルと推定、中国はCAGR 9.0％で成長予測

米国の核薬局市場は、2024年に17億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに17億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.0％と5.7％と予測されています。欧州では、ドイツがCAGR 3.8%で成長すると予測されています。

世界の核薬局市場- 主要動向と促進要因のまとめ

核薬局が現代のヘルスケアで注目を集める理由とは？

核薬局は、核画像診断や標的治療に使用される放射性医薬品の調製に重要な役割を果たすため、診断および治療医学の重要なコンポーネントとして台頭しています。腫瘍学、心臓病学、神経学における精密診断の需要が高まるにつれ、核医学薬局は、画像診断センターや病院に時間的制約のある患者特異的な放射性医薬品を供給する上で不可欠な存在となっています。これらの化合物は、生物学的プロセスを分子レベルで可視化し、疾患の早期発見や治療反応のより正確なモニタリングを可能にします。

画像診断に加え、核薬局は、治療と診断の機能が単一の放射性医薬品に統合されたセラノスティクス（theranostics）においても、その役割を拡大しています。この統合は、腫瘍の同定と治療の両方に特定のアイソトープを使用できる、より個別化された患者ケアのアプローチをサポートします。ヘルスケアは低侵襲で標的を絞った治療へとシフトしており、核薬局は臨床ワークフローにおいてますます中心的な役割を果たすことが期待されています。

放射性医薬品とアイソトープ生産の進歩はどのように成長を促進しているか？

新たな放射性医薬品の開発により、テクネチウム-99mやフッ素-18といった従来のトレーサーにとどまらず、核薬局の適用範囲が広がっています。ルテチウム-177やガリウム-68のようなアイソトープで標識されたペプチドや抗体など、より特異的な疾患ターゲットのために新しい薬剤が設計されています。これらの化合物は、前立腺がん、神経内分泌腫瘍、その他治療が困難な疾患の管理に使用され、特殊な核薬局操作の機会を生み出しています。

アイソトープ生産もまた変革期を迎えています。サイクロトロンやジェネレーターを利用した生産技術により、短寿命アイソトープの信頼性と現地での利用可能性が向上し、老朽化した原子炉への依存度が低下しています。自動合成モジュールと品質管理システムは、放射性医薬品の調製を改善し、投与量を標準化し、薬剤師の被ばくリスクを低減しています。これらの技術革新は、医療従事者への放射性医薬品のより迅速で安全かつスケーラブルな提供を支えています。

市場拡大の構造的・規制的要因は？

核薬局は、放射性物質の取り扱いに関する厳格な規制の下で事業を展開しています。国内および国際的な基準に準拠するためには、専門的なインフラ、スタッフのトレーニング、ライセンスが必要であり、大規模な運用が可能な施設の数は限られています。しかし、集中化されネットワーク化された放射性医薬品薬局の成長は、ヘルスケアシステムのロジスティクスの改善、廃棄物の削減、半減期の短い放射性医薬品のオンタイムデリバリーの確保に役立っています。

外来診断センターと統合ケアネットワークの台頭は、核薬局の拡大にさらに影響を与えています。多くの医療システムは、外部供給業者への依存を減らすために、院内あるいは提携する放射性医薬品製造機能に投資しています。新規の放射線治療薬に対する規制当局の迅速な対応と相まって、がん治療における公的および民間資金がサプライチェーンを強化し、市場開拓を加速しています。製薬会社、アイソトープメーカー、ヘルスケアプロバイダー間のパートナーシップも、臨床需要の高まりに対応するために生まれつつあります。

核薬局市場の成長は、いくつかの要因によってもたらされます。

腫瘍学、循環器学、神経学における核医学イメージングとセラノスティクスの利用が増加し、タイムリーで高品質な放射性医薬品への需要が高まっています。新規アイソトープや標的放射性トレーサーの開発により、臨床応用の幅が広がっています。自動合成技術とアイソトープ製造技術の進歩により、作業効率と安全性が向上しています。集中型放射性医薬品製造モデルの拡大により、一刻を争う診断薬への幅広いアクセスが可能になりつつあります。新しい放射線治療薬に対する規制当局の支援と個別化医療への投資の拡大により、核薬局の標準治療プロトコルへの統合が強化されています。これらの要因が相まって、核薬局市場は世界的に力強い成長軌道を形成しています。

セグメント

タイプ（施設タイプ,商業タイプ）;目的（診断,治療）

調査対象企業の例

  • Advanced Accelerator Applications（AAA）
  • Bayer AG（Radiopharma division）
  • Bracco Imaging S.p.A.
  • Cardinal Health, Inc.（Nuclear Pharmacy）
  • Curium Pharma
  • Eczacibasi-Monrol Nuclear Products
  • Eckert & Ziegler（Radiopharma division）
  • GE HealthCare（Nuclear Pharmacy Services）
  • IBA Molecular Imaging
  • Jubilant Radiopharma（Jubilant DraxImage）
  • Lantheus Medical Imaging, Inc.
  • Mallinckrodt plc.（Nuclear Imaging）
  • NTP Radioisotopes SOC Ltd.
  • Nihon Medi-Physics Co., Ltd.
  • Nordion Inc.（Sotera Health）
  • Novartis（Advanced Accelerator Applications）
  • PharmaLogic Holdings Corp.
  • Siemens Healthineers
  • Shine Technologies（SHINE Medical）
  • Telix Pharmaceuticals Limited

AIインテグレーション

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37521

Global Nuclear Pharmacy Market to Reach US$8.6 Billion by 2030

The global market for Nuclear Pharmacy estimated at US$6.1 Billion in the year 2024, is expected to reach US$8.6 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Institutional Type, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Commercial Type segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 9.0% CAGR

The Nuclear Pharmacy market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Nuclear Pharmacy Market - Key Trends & Drivers Summarized

Why Is Nuclear Pharmacy Gaining Prominence in Modern Healthcare?

Nuclear pharmacy is emerging as a critical component of diagnostic and therapeutic medicine due to its role in preparing radiopharmaceuticals used in nuclear imaging and targeted treatments. As demand rises for precision diagnostics in oncology, cardiology, and neurology, nuclear pharmacies are becoming essential in supplying time-sensitive, patient-specific radiotracers to imaging centers and hospitals. These compounds help visualize biological processes at the molecular level, enabling early detection of disease and more accurate monitoring of treatment response.

In addition to diagnostic imaging, nuclear pharmacy plays a growing role in theranostics-where therapeutic and diagnostic capabilities are combined in a single radiopharmaceutical. This integration supports a more personalized approach to patient care, where specific isotopes can be used to both identify and treat tumors. As healthcare shifts toward minimally invasive and targeted interventions, nuclear pharmacy is expected to play an increasingly central role in clinical workflows.

How Are Advancements in Radiopharmaceuticals and Isotope Production Driving Growth?

The development of new radiopharmaceuticals is expanding the scope of nuclear pharmacy beyond conventional tracers such as technetium-99m and fluorine-18. Novel agents are being designed for more specific disease targeting, including peptides and antibodies labeled with isotopes like lutetium-177 and gallium-68. These compounds are being used in the management of prostate cancer, neuroendocrine tumors, and other hard-to-treat conditions, creating opportunities for specialized nuclear pharmacy operations.

Isotope production is also undergoing transformation. Cyclotron and generator-based production techniques are improving reliability and local availability of short-lived isotopes, reducing dependency on aging nuclear reactors. Automated synthesis modules and quality control systems are improving radiopharmaceutical preparation, standardizing dosage, and reducing exposure risks to pharmacy personnel. These innovations are supporting faster, safer, and more scalable delivery of radiotracers to healthcare providers.

What Structural and Regulatory Factors Influence Market Expansion?

Nuclear pharmacy operates under strict regulatory controls given the handling of radioactive materials. Compliance with national and international standards requires specialized infrastructure, staff training, and licensing, which limits the number of facilities that can operate at scale. However, growth in centralized and networked radiopharmacies is helping healthcare systems improve logistics, reduce waste, and ensure on-time delivery of radiopharmaceuticals with short half-lives.

The rise of outpatient diagnostic centers and integrated care networks is further influencing nuclear pharmacy expansion. Many health systems are investing in in-house or partnered radiopharmacy capabilities to reduce reliance on external suppliers. Public and private funding in cancer care, coupled with regulatory fast-tracking of novel radiotherapeutics, is strengthening supply chains and accelerating market development. Partnerships between pharmaceutical companies, isotope producers, and healthcare providers are also emerging to meet rising clinical demand.

Growth in the nuclear pharmacy market is driven by several factors.

Increased use of nuclear imaging and theranostics in oncology, cardiology, and neurology is boosting demand for timely, high-quality radiopharmaceuticals. Development of novel isotopes and targeted radiotracers is expanding the range of clinical applications. Advances in automated synthesis and isotope production technologies are improving operational efficiency and safety. Expansion of centralized radiopharmacy models is enabling wider access to time-sensitive diagnostic agents. Regulatory support for new radiotherapeutics and growing investment in personalized medicine are reinforcing the integration of nuclear pharmacy into standard care protocols. These factors are collectively shaping a strong growth trajectory for the nuclear pharmacy market globally.

SCOPE OF STUDY:

The report analyzes the Nuclear Pharmacy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Institutional Type, Commercial Type); Purpose (Diagnostic, Therapeutic)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Advanced Accelerator Applications (AAA)
  • Bayer AG (Radiopharma division)
  • Bracco Imaging S.p.A.
  • Cardinal Health, Inc. (Nuclear Pharmacy)
  • Curium Pharma
  • Eczacibasi-Monrol Nuclear Products
  • Eckert & Ziegler (Radiopharma division)
  • GE HealthCare (Nuclear Pharmacy Services)
  • IBA Molecular Imaging
  • Jubilant Radiopharma (Jubilant DraxImage)
  • Lantheus Medical Imaging, Inc.
  • Mallinckrodt plc. (Nuclear Imaging)
  • NTP Radioisotopes SOC Ltd.
  • Nihon Medi-Physics Co., Ltd.
  • Nordion Inc. (Sotera Health)
  • Novartis (Advanced Accelerator Applications)
  • PharmaLogic Holdings Corp.
  • Siemens Healthineers
  • Shine Technologies (SHINE Medical)
  • Telix Pharmaceuticals Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Nuclear Pharmacy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Targeted Diagnostic Imaging Drives Growth in Nuclear Pharmacy Services
    • Expansion of PET and SPECT Imaging in Oncology, Cardiology, and Neurology Boosts Radiopharmaceutical Usage
    • Increased Availability of Short-Lived Isotopes Spurs Growth in Centralized and In-Hospital Nuclear Pharmacies
    • Advancements in Cyclotron and Generator Technologies Enhance On-Demand Radiotracer Production
    • Regulatory Approvals for New Radiolabeled Drugs Strengthen Market for Precision Diagnostic Tools
    • Shift Toward Personalized Medicine Throws the Spotlight on Radiotheranostics and Companion Diagnostics
    • Growing Use of Radiopharmaceuticals in Therapeutic Applications Expands Scope of Nuclear Pharmacy Operations
    • Integration of Automation and Robotics in Radiopharmacies Improves Accuracy, Safety, and Throughput
    • Expansion of Academic and Clinical Research Programs Fuels Demand for Custom Radiopharmaceutical Compounding
    • Rising Incidence of Chronic and Age-Related Diseases Accelerates Investment in Nuclear Imaging Infrastructure
    • Improvements in Cold-Chain Logistics and Dose Scheduling Support Wider Distribution of Time-Sensitive Isotopes
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nuclear Pharmacy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Nuclear Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Institutional Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Institutional Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Institutional Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Commercial Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Commercial Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Commercial Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Therapeutic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Therapeutic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • JAPAN
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • CHINA
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • EUROPE
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Nuclear Pharmacy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • FRANCE
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • GERMANY
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Nuclear Pharmacy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • INDIA
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Nuclear Pharmacy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Nuclear Pharmacy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Nuclear Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030
  • AFRICA
    • Nuclear Pharmacy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Nuclear Pharmacy by Type - Institutional Type and Commercial Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Nuclear Pharmacy by Type - Institutional Type and Commercial Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Nuclear Pharmacy by Type - Percentage Breakdown of Value Sales for Institutional Type and Commercial Type for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Nuclear Pharmacy by Purpose - Diagnostic and Therapeutic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Nuclear Pharmacy by Purpose - Percentage Breakdown of Value Sales for Diagnostic and Therapeutic for the Years 2014, 2025 & 2030

IV. COMPETITION